Obstructive Hypertrophic Cardiomyopathy (oHCM)

Cardiovascular
3
Pipeline Programs
2
Companies
3
Clinical Trials
1 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
1
Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

Cytokinetics
MYQORZOApproved
aficamten
Cytokinetics
oral2025

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Cytokinetics
CytokineticsSOUTH SAN FRANCISCO, CA
2 programs
2
1
AficamtenPhase 31 trial
AficamtenPhase 3
Active Trials
NCT05186818Completed282Est. Dec 2023
Bristol Myers Squibb
2 programs
MavacamtenN/A1 trial
MavacamtenN/A1 trial
Active Trials
NCT07383025Recruiting200Est. Nov 2029
NCT06338202Completed115Est. Dec 2024

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
2027
2028
2029
CytokineticsAficamten
Bristol Myers SquibbMavacamten
Bristol Myers SquibbMavacamten

Clinical Trials (3)

Total enrollment: 597 patients across 3 trials

NCT05186818CytokineticsAficamten

Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM

Start: Feb 2022Est. completion: Dec 2023282 patients
Phase 3Completed
NCT07383025Bristol Myers SquibbMavacamten

Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan

Start: May 2025Est. completion: Nov 2029200 patients
N/ARecruiting
NCT06338202Bristol Myers SquibbMavacamten

Real-World Effectiveness of Mavacamten in Canada

Start: Jun 2024Est. completion: Dec 2024115 patients
N/ACompleted

Related Jobs in Cardiovascular

Embedded Software and System Test Engineer (H/F)

Cardiawave
Levallois-Perret, France (Hybrid)
Just now

Territory Sales Manager - Iowa / Nebraska

HeartFlow
Cedar Rapids, IA; Des Moines, IA; Omaha, NE; Lincoln, NE
23h ago
From $150K/yr

Physician Program Director, Los Angeles

Johnson & Johnson
Danvers, Massachusetts, United States of America
Yesterday
$132K - $212K/yr

J&J MedTech Neurovascular Senior Financial Analyst, R&D

Johnson & Johnson
Irvine, California, United States of America
Yesterday
$79K - $128K/yr

Ingénieur d'Application Clinique (H/F) Dept. 54, 57, 67, 68, 25, 90

Johnson & Johnson
Issy-les-Moulineaux, France
Yesterday

Trainee Technical Specialist

Johnson & Johnson
Leeds, West Yorkshire, United Kingdom
Yesterday

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 597 patients
2 companies competing in this space

Related Indications

Heart Failure(334)Hypertension(333)Coronary Artery Disease(295)Atrial Fibrillation(288)Pulmonary Arterial Hypertension(103)Acute Coronary Syndrome(62)Pulmonary Hypertension(55)Essential Hypertension(32)Coronary Heart Disease(28)Aortic Valve Stenosis(27)